天境生物 IMAB 深 沪
已收盘 08-01 16:00:00 美东时间
2.62
+0.610
+30.35%
华盛通- 最 高3.44
- 今 开2.26
- 成交量 4455.05万股
- 最 低 2.25
- 昨 收 2.01
- 总市值 2.14亿
- 52周最高 3.44
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 0.595
- 委 比 -47.70%
- 总股本 8166.03万
- 历史最高 85.40
- 量 比 66.72
- 振 幅 59.20%
- 历史最低 0.595
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多I-MAB shares are trading higher after the company announced that Everest will invest $30.9 million in the company. Additionally, the company announced a $65 million ADS offering.
I-MAB shares are trading higher after the company announced that Everest will i...
08-01 21:10
I-Mab prices $65M ADS offering
I-Mab (NASDAQ:IMAB) has priced a public offering of 33.3 million American Depositary Shares (ADSs) at $1.95 per ADS, raising about $65 million in gross proceeds. All shares are being sold by the compa...
08-01 20:13
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 100.5% to $7.52 during Wednes...
07-31 01:07
六旬女科学家，把公司68亿卖给一个「90后」
原标题：六旬女科学家，把公司68亿卖给一个「90后」 来源：中国企业家杂志 手上有100亿元现金的药企有不少，中生对礼新的收购是并购时代的起点？ 中国生物制药...
07-24 11:14
4882万元收购一家公司，买断CLDN18.2核心双抗权利
（来源：动脉新医药） 7月17日，美国天境生物（I-Mab）宣布达成最终协议，收购Bridge Health 100%股权。此次交易将为公司带来其CLDN18...
07-18 17:51
I-Mab Acquires Bridge Health to Boost Givastomig Portfolio
I-MAB ( ($IMAB) ) has shared an update. On July 17, 2025, I-Mab announced the a...
07-17 19:28
5个月480亿美元，当出海成为Biotech商业化“主逻辑”
（来源：动脉新医药） 国内Biotech出海持续火热。 7月9日，生物科技公司维泰瑞隆与诺华达成战略协议，授予诺华独家选择权，以收购其专有的“脑部递送模...
07-17 17:05
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
I-Mab acquires 100% ownership of Bridge Health, securing upstream rights to CLDN18.2 parental antibody for bispecific applications and eliminating future royalties, enhancing the value of givastomig. The deal strengthens intellectual property and streamlines development for the promising Claudin 18.2-targeted therapy.
07-17 11:00
I-Mab to Join Virtual Biotech Event, Talks Cancer Treatment Progress With Investors
I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will
07-14 19:07
